Jounce Therapeutics GAAP EPS of -$0.59 misses by $0.27

• Jounce Therapeutics press release (NASDAQ:JNCE): Q4 GAAP EPS of -$0.59 misses by $0.27.
• As of December 31, 2021, cash, cash equivalents and investments were $220.2 million, compared to $213.2 million as of December 31, 2020.
• FY22 Guidance:
• Gross cash burn on operating expenses and capital expenditures for the full year 2022 is expected to be approximately $115.0 million to $130.0 million.
• Existing cash, cash equivalents and investments to be sufficient to enable the funding of its operating expenses and capital expenditure requirements through the third quarter of 2023.